Showing 1 - 5 results of 5 for search 'David Muccino', query time: 0.03s Refine Results
  1. 1
    Leicester Cough Questionnaire validation and clinically important thresholds for change in refractory or unexplained chronic cough

    Leicester Cough Questionnaire validation and clinically important thresholds for change in refractory or unexplained chronic cough by Allison Martin Nguyen, Jonathan Schelfhout, David Muccino, Elizabeth D. Bacci, Carmen La Rosa, Margaret Vernon, Surinder S. Birring

    Published 2022-05-01
    Get full text
    Article
  2. 2
    A phase 3, randomized, double-blind, clinical study to evaluate the long-term safety and efficacy of gefapixant in Japanese adult participants with refractory or unexplained chronic cough

    A phase 3, randomized, double-blind, clinical study to evaluate the long-term safety and efficacy of gefapixant in Japanese adult participants with refractory or unexplained chroni... by Akio Niimi, Hironori Sagara, Masashi Kikuchi, Ichiro Arano, Asako Sato, Masayoshi Shirakawa, Carmen La Rosa, David Muccino

    Published 2022-10-01
    Get full text
    Article
  3. 3
    Validation of a visual analog scale for assessing cough severity in patients with chronic cough

    Validation of a visual analog scale for assessing cough severity in patients with chronic cough by Allison Martin Nguyen, Elizabeth D. Bacci, Margaret Vernon, Surinder S. Birring, Carmen La Rosa, David Muccino, Jonathan Schelfhout

    Published 2021-10-01
    Get full text
    Article
  4. 4
    Patient characteristics and triggers eliciting refractory chronic cough

    Patient characteristics and triggers eliciting refractory chronic cough by David Muccino, George Philip, S.S. Birring, A.H. Morice, M.R. Sher, L.P. Mcgarvey, M.M. Kitt, A.M. Tershakovec, Z.J. Xu, J.A. Smith

    Published 2020-08-01
    Get full text
    Article
  5. 5
    Rationale and design of two, phase 3, randomized controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory and unexplained chronic cough

    Rationale and design of two, phase 3, randomized controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory and unexplained chronic cough by David Muccino, George Philip, A.H. Morice, S.S. Birring, L. Mcgarvey, P.V. Dicpinigaitis, I.D. Pavord, A.M. Tershakovec, M.M. Kitt, C. Assaid, J.A. Smith

    Published 2020-08-01
    Get full text
    Article

Search Tools: